---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-005305"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2021-12-21T23:59:59+00:00"
generated_at: "2026-06-27T23:22:36.290633+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcus closes Gilead amendment; receives $725M option fees for 3 programs

## Summary
- Closed amendment to Option, License and Collaboration Agreement with Gilead on Dec 21, 2021.
- Gilead acquires rights to anti-TIGIT (domvanalimab/AB308), adenosine antagonist (etrumadenant), CD73 (quemliclustat).
- Gilead to pay $725 million in option fees, expected early Q1 2022.

## SEC filing metadata
- accession: 0000950170-21-005305
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2021-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017021005305/0000950170-21-005305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017021005305/rcus-20211221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-005305
- JSON: https://secwatch.observer/filing/0000950170-21-005305.json
- Plain text: https://secwatch.observer/filing/0000950170-21-005305.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.